AUTHOR=Zhang Tianyu , Lin Zhili , Zheng Ziwei , Wang Quanqiang , Zhou Shujuan , Zhang Bingxin , Zheng Dong , Chen Zixing , Zheng Sisi , Zhang Yu , Lin Xuanru , Dong Rujiao , Chen Jingjing , Qian Honglan , Hu Xudong , Zhuang Yan , Zhang Qianying , Jin Zhouxiang , Jiang Songfu , Ma Yongyong 

TITLE=Prognostic significance of β2-microglobulin decline index in multiple myeloma

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1322680

DOI=10.3389/fonc.2024.1322680

ISSN=2234-943X

ABSTRACT=We aimed to assess the prognostic significance of β2-microglobulin decline index (β2M DI) in multiple myeloma (MM). 150 MM patients diagnosed with MM were enrolled in this study. Cox proportional hazards model was used to analyze the uni-and multivariate prognosis in training cohort(n=105). β2M DI showed significant correlation with prognosis in both uni-and multivariate analyses and had a good correlation with complete response (CR) rate and deep remission rate. A new combined prognostic model containing β2M DI was built up based on the data in training cohort. The ROC and calibration curves in validation cohort(n=45) indicated a good predictive performance of the new model. Based on the median risk score of the training group, we classified patients into high-and low-risk groups. In both training and validation groups, patients in the low-risk group had 2 longer overall survival (OS) time than that in the high-risk group(p<0.05). In conclusion, β2M DI is a good predictive index for predicting treatment response and survival time in MM patients. The prognostic model added with β2M DI showed a better correlation with OS.